Furthermore, research findings revealing the immunomodulatory functions of AXL have provided strong support for the combinational treatment of AXL inhibition and ICI treatment in primary tumor models of breast and lung cancers [9, 56, 57]. This evidence concerns the gene AXL and lung cancer.